Anna Senczuk
Senior Director & Head of Novel Modalities, Discovery Research CSL Seqirus
Anna Senczuk is Senior Director at CSL, bringing deep expertise in nucleic acids and bioprocess development from leadership roles across Resilience, GreenLight Biosciences, Shire, Pfizer, Takeda & Amgen. With a strong background in purification, protein chemistry, and advanced process development, she has led teams advancing RNA‑based modalities and innovative manufacturing strategies. Anna holds an M.Sc. and B.Sc. in Biochemistry from the University of Calgary and has over two decades of experience in biopharmaceutical R&D.
Seminars
Advancing novel RNA therapeutics requires early, aligned decisions that strengthen manufacturability and regulatory readiness. This workshop provides a practical framework for designing circular and self-amplifying RNA constructs, anticipating CMC risks and building streamlined development paths that reduce rework and accelerate IND timelines.
This workshop will gather experts to discuss:
- Accelerate IND timelines by applying structured design principles that cut construct development cycles and improve potency/durability.
- Prevent scale-up failures by identifying manufacturability and CMC risks early, ensuring GMP consistency and reducing costly rework.
- Minimize IND deficiencies by aligning regulatory expectations with analytical and CMC strategies, reducing late-stage surprises.
- Unify design, manufacturing, and regulatory teams to enable faster decision-making and reduce development bottlenecks.
This workshop is for:
R&D leaders, CMC teams, program directors, regulatory strategists and platform developers seeking a more predictable and accelerated path from sequence design to IND
